B-Cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after hematopoietic stem cell transplantation:: Association with fludarabine and anti-thymocyte globulib containing conditioning regimen

被引:12
作者
Lange, A
Klimczak, A
Dlubek, D
Dybko, J
机构
[1] Polish Acad Sci, Ludwig Hirszfeld Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland
[2] Lower Silesian Ctr Cellular Transplantat, Wroclaw, Poland
[3] Natl Polish Bone Marrow Donor Registry, Wroclaw, Poland
关键词
D O I
10.1016/j.transproceed.2003.10.043
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Fifty-eight patients who received hematopoietic stem cell transplants during, a 3-year period in our unit were followed for the symptoms of posttransplant B-cell lymphoproliferative syndrome (B-cell PTLD). Three cases showed lymph node enlargement; in 14, there was an excess of B cells in the blood. Histochemical staining of lymph nodes revealed CD20(+) cell expansion in two cases, and in one, CD38(+) and CD138(+) cells. Kappa and lambda staining revealed poly- or oligoclonal expansion, which was characterized by the presence of Ki67(+) cells in 10% to 50% of cells. In 14 cases, an excess of CD20(+) cells were observed in blood. Clinical analysis revealed that patients with B-cell expansion in blood and/or in lymph nodes frequently showed fever and that some subjects displayed arthralgia, hemolytic anemia, and hepatitis. LMP-1-positive cells were observed in lymph nodes as well as EBV copies, whereas only a proportion of patients with the excessive CD20(+) cells in blood were EBV positive. Notably, lymph node enlargement and CD20(+) blood excess occurred significantly more frequently among patients receiving a Fludarabine (Flu) and anti-thymocyte globulin (ATG) conditioning regimen than those whose treatment lacked Flu independent of whether they received ATG (0.80 vs 0.44; P=.036).
引用
收藏
页码:3093 / 3095
页数:3
相关论文
共 5 条
[1]  
Curtis RE, 1999, BLOOD, V94, P2208
[2]   Malignancies after hematopoietic stem cell transplantation:: Many questions, some answers [J].
Deeg, HJ ;
Socié, G .
BLOOD, 1998, 91 (06) :1833-1844
[3]  
GRATAMA JW, 1994, BONE MARROW TRANSPL, P429
[4]  
Orazi A, 1997, AM J CLIN PATHOL, V107, P419
[5]   Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT [J].
van Esser, JWJ ;
van der Holt, B ;
Meijer, E ;
Niesters, HGM ;
Trenschel, R ;
Thijsen, SFT ;
van Loon, AM ;
Frassoni, F ;
Bacigalupo, A ;
Schaefer, UW ;
Osterhaus, ADME ;
Gratama, JW ;
Löwenberg, B ;
Verdonck, LF ;
Cornelissen, JJ .
BLOOD, 2001, 98 (04) :972-978